Kaoru Tsuchiya

Musashino, 1808610, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 129 publications

Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study.

Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study.

Journal: Journal of clinical medicine

Published: June 15, 2026

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Journal: Anticancer research

Published: May 14, 2026

Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis.

Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis.

Journal: Nutrients

Published: April 01, 2026

Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography.

Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography.

Journal: Diagnostics (Basel, Switzerland)

Published: March 30, 2026

Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational study.

Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational study.

Journal: European journal of gastroenterology & hepatology

Published: November 17, 2025

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds.

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds.

Journal: Journal of clinical medicine

Published: October 07, 2025

Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study.

Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: July 17, 2025

Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).

Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).

Journal: Journal of gastroenterology

Published: June 13, 2025

Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older.

Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older.

Journal: PloS one

Published: June 08, 2025

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: June 06, 2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Hepatology international

Published: April 30, 2025

Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.

Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study.

Journal: Liver cancer

Published: December 26, 2024

Showing 1-12 of 129

Last Updated: 09/26/2026